Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02397382 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis
A Phase 1 study of Psoriasis, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 8
- Study locations
NCT02397382 is a Phase 1 study of Psoriasis that has completed, run by Janssen Research & Development. The registered enrollment target is 16 participants, below the 489-participant average among 125 other Psoriasis trials with a reported enrollment target (97% lower). The trial reports 8 study locations across 7 states.
The verdict
NCT02397382, a Phase 1 study of Psoriasis, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this study is to evaluate the potential effects of a single dose of 200 milligram (mg) guselkumab on the plasma concentrations of a cocktail of representative probe substrates of Cytochrome P450 isozymes (CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2) in participants with moderate to severe psoriasis.
Conditions Studied
Interventions
- DRUG Guselkumab
- DRUG Midazolam
- DRUG Omeprazole
- DRUG Warfarin
- DRUG Dextromethorphan
Study Locations (8)
Pennsylvania
- - Duncansville
- - Pittsburgh
Alabama
- - Anniston
California
- - North Hollywood
Florida
- - Orlando
Georgia
- - Atlanta
North Carolina
- - High Point
Texas
- - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2015-06-18 |
| Est. Completion | 2016-08-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02397382
The ClinicalTrials.gov registry entry for NCT02397382 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 489-participant average among 125 other Psoriasis trials with a reported enrollment target (97% lower). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 5 interventions - of which Guselkumab is the first listed.
NCT02397382 reports 8 study locations spanning 7 distinct geographic areas - top geographies include Pennsylvania, Alabama, California.
Frequently Asked Questions
What is clinical trial NCT02397382 about?
NCT02397382 is a clinical study titled "Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis". The purpose of this study is to evaluate the potential effects of a single dose of 200 milligram (mg) guselkumab on the plasma concentrations of a cocktail of representative probe substrates of Cytochrome P450 isozymes (CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2) in participants with moderate to se...
What is the current status of trial NCT02397382?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2015-06-18. Estimated completion is 2016-08-31.
What conditions does trial NCT02397382 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT02397382?
The interventions under investigation include: Guselkumab (DRUG), Midazolam (DRUG), Omeprazole (DRUG), Warfarin (DRUG), Dextromethorphan (DRUG).
Who is sponsoring clinical trial NCT02397382?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02397382 being conducted?
This trial has 8 study locations across Alabama, California, Florida, Georgia, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Evaluate the Safety and Pharmacokinetics/Pharmacodynamics of HS-20118
RECRUITING · Phase 1
-
Study of SFA002 in Patients with Mild to Moderate Psoriasis Plaques
RECRUITING · Phase 1
-
Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis
RECRUITING · Phase 1
-
Study Evaluating The Safety And Tolerability Of ILV-094 In Subjects With Psoriasis
COMPLETED · Phase 1
-
An Investigational Study of Cyclosporine on Experimental Medication BMS-986165 in Healthy Male Participants
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.